Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women With Osteoporosis

NCT00259298 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00259298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00259298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women With Osteoporosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2005
Completion date
July 31, 2009
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis